Recently, the District Court in Düsseldorf lifted several ex-parte preliminary injunctions granted for Merck Sharpe & Dohme Corp. (MSD) against various generic companies. Subject of the proceedings is the cholesterol-lowering combination product Inegy®. Inegy® is a fixed dose combination of the actives ingredients ezetimibe and simvastatin. Dr Derk Vos (Maiwald) represented Hexal in the proceedings.
The complete The SPC Blog article can be downloaded here: